

# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

**Date: 12<sup>th</sup> August, 2025**

To, The Secretary ( <b>DCS/Compliance</b> ), Corporate Relationship Department, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary ( <b>Listing/Compliance</b> ), Corporate Relationship Department, <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

**Subject: Outcome of Board Meeting held on Tuesday 12<sup>th</sup> August, 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)**

Dear Sir/Madam,

With reference to the above captioned subject and in pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 04/2025-26) held on today i.e., Tuesday, 12<sup>th</sup> Day of August, 2025, has inter alia, considered and approved the following businesses:

1. Un-Audited Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2025 along with limited Review Report thereon. **(Copy of financial results enclosed herewith).**
2. Upon the recommendation of the Audit Committee, appointment of Joshi Sahay & Company, Practicing Company Secretaries as Secretarial Auditors of the Company for a period of 5 (five) consecutive years commencing from FY 2025-2026 till FY 2029-2030 and fix their remuneration, subject to approval of the shareholders of the Company at the ensuing 40<sup>th</sup> Annual General Meeting of the Company.
3. Based on recommendation of the Nomination and Remuneration Committee, approval of re-appointment of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non Executive Independent Director of the Company for a second and final term of five consecutive years w.e.f. 25<sup>th</sup> August, 2025 to 24<sup>th</sup> August, 2030.
4. Based on recommendation of the Nomination and Remuneration Committee, approval of re-appointment of Mr. Satish Beohar (DIN: 09220291) as a Non Executive Independent Director of the Company for a second and final term of five consecutive years w.e.f. 30<sup>th</sup> June, 2026 to 29<sup>th</sup> June, 2031 subject to approval of the shareholders of the Company at the ensuing 40<sup>th</sup> Annual General Meeting.
5. Approval of Board's Report on the Operation of the Company along with required annexure and Corporate Governance Report & Management Discussion and Analysis Report for the year ended March 31, 2025.
6. Convening of 40<sup>th</sup> Annual General Meeting (AGM) on Saturday, 27<sup>th</sup> day of September, 2025 at 03.00 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

7. Constitution of Finance Committee of Board of Directors w.e.f. 12<sup>th</sup> August, 2025 in the following manner: -

S. No.	Name of Directors	Category of Directors	Designation in the Committee
1	Mr. Ketan Shah	Whole Time Director	Chairperson
2	Mr. Meet Shah	Non-Executive Non-Independent Director	Member

8. Shifting of registered Office of the Company within the city from i.e. **11/12, Sector E Sanwer Road, Indore, Madhya Pradesh, India, 452015 to 12/B Pologround, Indore, Madhya Pradesh, India, 452015 with effect from 01.09.2025.**
9. Based on recommendation of the Nomination and Remuneration Committee, Change in designation of Mr. Ketan Shah (DIN: 08818212) from Whole-Time Director to Chairman and Managing Director of the Company for a period of 3 (Three) years w.e.f. 12<sup>th</sup> August, 2025 to 11<sup>th</sup> August, 2028 subject to approval of shareholders at the ensuing Annual General Meeting.
10. Other routine businesses with the permission of Chair.

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 are being submitted separately in pdf and xbrl form with in prescribed time limit.

Furthermore, copy of Un-Audited Financial Results of the Company shall also be submitted in integrated filing financials XBRL within prescribed time limit from the conclusion of Board Meeting.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. [www.biofilgroup.net](http://www.biofilgroup.net) and on the website of the Stock Exchanges i.e., at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com). Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers with in prescribed time limit.

The Meeting of the Board of Directors commenced at 04.00 P.M. and concluded at 05.50 P.M.

The above information will also be available on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net).

You are requested to please take on record the same.

Thanking you.

Yours Faithfully,

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**APOORV JAIN  
COMPANY SECRETARY & COMPLIANCE OFFICER  
M. NO. A71739**

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
The Board of Directors  
Biofil Chemicals and Pharmaceuticals Limited  
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 30<sup>th</sup> June, 2025 and year to date from 01<sup>st</sup> April, 2025 to 30<sup>th</sup> June, 2025 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be



aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**  
Chartered Accountants

FRN: 006179C



**CA. SUNIL MAHESHWARI**

Partner

M. No. 403346

Place: Indore

Date: 12/08/2025

UDIN: 25403346BMIIMG2694



# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709

Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) 452015

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

Amount in Lakhs except EPS)

## Statement of Unaudited Financial Results for the quarter ended 30th June 2025

Sr No.	Particulars	Quarter Ended			Previous Year Ended
		June 30, 2025	June 30, 2024	March 31, 2025	March 31, 2025
		Un-Audited	Un-Audited	Audited	Audited
I	Revenue from Operation	643.26	844.34	835.10	3340.22
II	Other Income	283.20	2.94	23.67	30.52
III	<b>Total Income</b>	<b>926.46</b>	<b>847.28</b>	<b>858.77</b>	<b>3370.74</b>
IV	<b>Expenses</b>				
	(a) Cost of materials consumed	117.14	68.62	207.56	531.46
	(b) Purchases of stock-in-trade	974.06	743.01	525.59	2632.06
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(497.91)	(40.08)	31.90	(78.91)
	(d) Employee benefits expense	21.04	13.86	24.89	78.50
	(e) Finance Cost	0.93	1.07	0.75	3.69
	(f) Depreciation and Amortisation Expense	6.60	9.87	8.34	37.96
	(g) Other expenses	28.35	28.13	34.36	92.37
	1. Manufacturing Expenses	5.67	7.37	11.99	38.95
	2. Administrative Expenses	5.85	5.85	5.18	26.65
	<b>Total expenses</b>	<b>650.21</b>	<b>824.48</b>	<b>833.39</b>	<b>3297.13</b>
V	<b>Profit/ (Loss) before exceptional items and tax</b>	<b>276.25</b>	<b>22.80</b>	<b>25.38</b>	<b>73.61</b>
VI	<b>Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
VII	<b>Profit/ (Loss) before tax</b>	<b>276.25</b>	<b>22.80</b>	<b>25.38</b>	<b>73.61</b>
VIII	<b>Tax expense:</b>				
	(1) Current tax	35.15	5.87	8.58	21.00
	(2) Deferred tax	0.00	0.00	(3.17)	(3.17)
	<b>Total Tax expenses</b>	<b>35.15</b>	<b>5.87</b>	<b>5.42</b>	<b>17.83</b>
IX	<b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
X	<b>Profit/(Loss) for the period from continuing operation</b>	<b>241.10</b>	<b>16.93</b>	<b>19.96</b>	<b>55.78</b>
XI	<b>Profit/(Loss) for the period for dis-continued operation</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XII	<b>Tax expenses of discontinued operation</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit/(Loss) for the period for dis-continued operation after tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIV	<b>Profit/ (Loss) for the period</b>	<b>241.10</b>	<b>16.93</b>	<b>19.96</b>	<b>55.78</b>
XV	<b>Other Comprehensive Income</b>	<b>0.00</b>		<b>0.00</b>	
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	2.80	2.80
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	(0.71)	(0.71)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
XVI	<b>Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)</b>	<b>241.10</b>	<b>16.93</b>	<b>22.06</b>	<b>57.87</b>
XVII	<b>Paid-Up equity share capital (face value of Rs 10/- each)</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>
XVIII	<b>Reserves (Excluding Revaluation Reserve)</b>				<b>(125.42)</b>
XIX	<b>Earnings per equity shares (for continuing operation):</b>				
	(1) Basic (Rs)	1.48	0.10	0.12	0.34
	(2) Diluted (Rs)	1.48	0.10	0.12	0.34

<b>XX</b>	<b>Earnings Per Equity Share (for discontinued operation)</b>				
	(1) Basic (Rs)	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00
<b>XXI</b>	<b>Earnings Per Equity Share (for continuing &amp; discontinued operation)</b>				
	(1) Basic (Rs)	1.48	0.10	0.12	0.34
	(2) Diluted (Rs)	1.48	0.10	0.12	0.34

1 The above Un-Audited Financial Results for the Quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 12th August, 2025. The above results have been reviewed by Statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2 This financial results has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments  
a. Pharma Product  
b. Chemicals Division

5 The aforesaid un-audited Financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers with in prescribed time limit.

6 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.

7 The net profit of the Company for the quarter ended 30th June, 2025 has been increased due to disposal of undertaking situated at 11/12, Sector 'E', Sanwer Road Industrial Area, Indore - 452015 Madhya Pradesh after obtaining the approval from the members of the company.

Date : 12th August, 2025

Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

  
KETAN SHAH  
WHOLE TIME DIRECTOR  
(DIN: 08818212)



**Segmentwise Revenue, Results and Capital Employed for quarter ended 30th June-2025**


( Amount in Lakhs)

S.No.	Particulars	Quarter Ended			Previous Year Ended
		June 30, 2025	June 30, 2024	March 31, 2025	March 31, 2025
		Un-Audited	Un-Audited	Audited	Audited
1	<b>Segment Revenue</b>				
	Pharma Division	484.75	739.63	539.43	2,666.04
	Chemical Division	158.51	104.71	295.66	674.18
	<b>Net sales/Income From Operations</b>	<b>643.26</b>	<b>844.34</b>	<b>835.10</b>	<b>3,340.22</b>
2	<b>Segment Results (Profit)(+)/ Loss (-) before tax and interest</b>				
	Pharma Division	269.74	1.95	(6.99)	(14.38)
	Chemical Division	7.37	21.71	28.89	87.19
	<b>Total Segment Profit Before Tax</b>	<b>277.11</b>	<b>23.66</b>	<b>21.90</b>	<b>72.81</b>
	Interest Income	0.06	0.05	4.31	4.42
	Interest Expenses	0.92	0.91	0.83	3.62
	Other Unallocable Income net of Expenditure				
	<b>Profit Before Tax</b>	<b>276.25</b>	<b>22.80</b>	<b>25.38</b>	<b>73.61</b>
3	<b>Capital Employed</b>				
	<b>Segment Assets (A)</b>				
	Pharma Division	3,481.58	2,927.55	3,472.49	3,472.49
	Chemical Division	1,627.23	2,135.96	1,623.55	1,623.55
	<b>Total (A)</b>	<b>5,108.81</b>	<b>5,063.51</b>	<b>5,096.04</b>	<b>5,096.04</b>
	<b>Segment Liabilities (B)</b>				
	Pharma Division	2,290.92	2,306.72	2,919.95	2,919.95
	Chemical Division	698.62	878.17	297.93	297.93
	<b>Total (B)</b>	<b>2,989.55</b>	<b>3,184.89</b>	<b>3,217.88</b>	<b>3,217.88</b>
4	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>				
	Pharma Division	1,190.66	620.83	552.54	552.54
	Chemical Division	928.60	1,257.79	1,325.62	1,325.62
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>2,119.26</b>	<b>1,878.62</b>	<b>1,878.16</b>	<b>1,878.16</b>

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Date : 12th August, 2025

Place : Indore

  
**KETAN SHAH**  
 WHOLE TIME DIRECTOR  
 ( DIN: 08818212)

